CoChat

Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis

Open access
Mills, Jeffrey A., Strawn, Jeffrey R. · 2020 · Journal of the American Academy of Child & Adolescent Psychiatry
Cited by 56

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective: To compare antidepressant-related adverse events (AEs), suicidality and AE-related discontinuation in double-blind, placebo-controlled trials of pediatric patients with OCD and anxiety disorders treated with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Method: MEDLINE, PubMed, Web of Science, PsycINFO and Embase were searched for peer-reviewed, English-language articles from inception through March 1, 2019. We identified prospective, randomized, SSRI and SNRI studies in patients <18 years of age with OCD, generalized, separation or social anxiety disorders. AE rates were extracted and antidepressant-placebo differences examined using Bayesian hierarchical models (BHM). Then posterior estimates of relative risk (RR) were determined for each AE by medication class and disorder. Results: Data were included from 18 trials (2631 patients) and 7 medications (16 SSRI and 4 SNRI trials). Compared to placebo, SSRIs were associated with a greater likelihood of AE-related discontinuation (RR: 3.59, Credible Interval [CrI]: 0.019 to 0.067, p=0.0003), activation (RR: 2.39, CrI: 0.048 to 0.125, p=0.003), sedation (RR: 1.94, CrI: 0.035 to 0.157, p=0.002), insomnia (RR: 1.93, CrI: 0.040 to 0.149, p=0.001), abdominal pain (RR: 1.53, CrI: 0.032 to 0.164, p=0.005) and headache (RR: 1.24, CrI: 0.003 to 0.139, p=0.04). Activation was more common with SSRI (vs. SNRIs, RR: 1.32, CrI: 0.018 to 0.114, p=0.007). Neither SSRIs nor SNRIs were associated with treatment-emergent suicidality. Conclusions: In pediatric OCD and anxiety disorders, SSRIs as compared to placebo are associated with distinct adverse events (AEs) and greater AE-related discontinuation, although their tolerability does not differ between anxiety disorders and OCD. SSRIs are more likely than SNRIs to produce activation. Class-related AEs are important for clinicians to consider, particularly in light of data suggesting differences in class-related efficacy. While SSRIs are superior to SNRIs and the treatment of choice for anxiety, for youth who become activated on SSRIs, SNRIs might represent a good second choice given their reported efficacy and lower risk of activation

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2019.10.013

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 43

  1. Alderman, 1998, Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy, J Am Acad Child Adolesc Psychiatry, 37, 386, 10.1097/00004583-199804000-00016 · DOI
  2. Bushnell, 2018, Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications, J Clin Psychiatry, 79, 10.4088/JCP.16m11415 · DOI · Paper page
  3. Strawn, 2015, A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder, J Am Acad Child Adolesc Psychiatry, 54, 283, 10.1016/j.jaac.2015.01.008 · DOI
  4. Rynn, 2007, Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials, Am J Psychiatry, 164, 290, 10.1176/ajp.2007.164.2.290 · DOI · Paper page
  5. Rynn, 2001, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder, Am J Psychiatry, 158, 2008, 10.1176/appi.ajp.158.12.2008 · DOI · Paper page
  6. Watson, 2008, Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder, J Child Psychol Psychiatry, 49, 489, 10.1111/j.1469-7610.2007.01875.x · DOI · Paper page
  7. Geller, 2003, Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder, Am J Psychiatry, 160, 1919, 10.1176/appi.ajp.160.11.1919 · DOI · Paper page
  8. Wang, 2017, Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis, JAMA Pediatr, 171, 1049, 10.1001/jamapediatrics.2017.3036 · DOI · Paper page
  9. Varigonda, 2016, Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 55, 851, 10.1016/j.jaac.2016.07.768 · DOI · Paper page
  10. Reinblatt, 2009, Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents, J Child Adolesc Psychopharmacol, 19, 119, 10.1089/cap.2008.040 · DOI
  11. Luft, 2018, Antidepressant-induced activation in children and adolescents: risk, recognition and management, Curr Probl Pediatr Adolesc Health Care, 48, 50
  12. Safer, 2006, Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents, J Child Adolesc Psychopharmacol, 16, 159, 10.1089/cap.2006.16.159 · DOI · Paper page
  13. Rynn, 2015, Child/adolescent anxiety multimodal study: evaluating safety, J Am Acad Child Adolesc Psychiatry, 54, 180, 10.1016/j.jaac.2014.12.015 · DOI
  14. Reid, 2015, Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial, J Psychiatr Res, 71, 140, 10.1016/j.jpsychires.2015.10.006 · DOI
  15. Strawn, 2019, Switching selective serotonin reuptake inhibitors in adolescents with selective serotonin reuptake inhibitor-resistant major depressive disorder: balancing tolerability and efficacy, J Child Adolesc Psychopharmacol, 29, 250, 10.1089/cap.2018.0145 · DOI
  16. Connolly, 2007, Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders, J Am Acad Child Adolesc Psychiatry, 46, 267, 10.1097/01.chi.0000246070.23695.06 · DOI · Paper page
  17. Quintana, 2017, Bayesian analysis: using prior information to interpret the results of clinical trials, JAMA, 318, 1605, 10.1001/jama.2017.15574 · doi:10.1001/jama.2017.15574
  18. Lewis, 2018, Time for clinicians to embrace their inner bayesian?, JAMA, 320, 2208, 10.1001/jama.2018.16916 · DOI
  19. Gelman, 2014, Understanding predictive information criteria for Bayesian models, Stat Comput, 24, 997, 10.1007/s11222-013-9416-2 · DOI · Paper page
  20. McGlothlin, 2018, Bayesian hierarchical models, JAMA, 320, 2365, 10.1001/jama.2018.17977 · DOI
  21. Varigonda, 2015, Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder, J Am Acad Child Adolesc Psychiatry, 54, 557, 10.1016/j.jaac.2015.05.004 · DOI
  22. Riddle, 1992, Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder, J Am Acad Child Adolesc Psychiatry, 31, 1062, 10.1097/00004583-199211000-00011 · DOI · Paper page
  23. Aldrich, 2019, Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders, Front Pharmacol, 10, 99, 10.3389/fphar.2019.00099 · DOI · Paper page
  24. Mills JA, Strawn JR. Probabilistic biostatistics with Julia. In: JuliaCon Proceedings; 2019:1–6. Baltimore, Maryland, July 2019.
  25. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  26. Bezanson, 2017, Julia: a fresh approach to numerical computing, SIAM Review, 59, 65, 10.1137/141000671 · DOI · Paper page
  27. Ge, 2018, Turing: a language for flexible probabilistic inference, Proc Twenty-First Int Conf Artif Intell Stat, 84, 1682
  28. Moher, 2009, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 · DOI · Paper page
  29. Birmaher, 2003, Fluoxetine for the treatment of childhood anxiety disorders, J Am Acad Child Adolesc Psychiatry, 42, 415, 10.1097/01.CHI.0000037049.04952.9F · DOI · Paper page
  30. Geller, 2001, Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial, J Am Acad Child Adolesc Psychiatry, 40, 773, 10.1097/00004583-200107000-00011 · DOI · Paper page
  31. Riddle, 2001, Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial, J Am Acad Child Adolesc Psychiatry, 40, 222, 10.1097/00004583-200102000-00017 · DOI · Paper page
  32. Geller, 2004, Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial, J Am Acad Child Adolesc Psychiatry, 43, 1387, 10.1097/01.chi.0000138356.29099.f1 · DOI · Paper page
  33. March, 1998, Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial, JAMA, 280, 1752, 10.1001/jama.280.20.1752 · DOI · Paper page
  34. Crawley, 2014, Somatic complaints in anxious youth, Child Psychiatry Hum Dev, 45, 398, 10.1007/s10578-013-0410-x · DOI · Paper page
  35. Alfano, 2007, Sleep-related problems among children and adolescents with anxiety disorders, J Am Acad Child Adolesc Psychiatry, 46, 224, 10.1097/01.chi.0000242233.06011.8e · DOI · Paper page
  36. Caporino, 2017, Sleep-related problems and the effects of anxiety treatment in children and adolescents, J Clin Child Adolesc Psychol, 46, 675, 10.1080/15374416.2015.1063429 · DOI
  37. Alfano, 2011, Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation, J Anxiety Disord, 25, 835, 10.1016/j.janxdis.2011.04.004 · DOI · Paper page
  38. Storch, 2008, Sleep-related problems in pediatric obsessive-compulsive disorder, J Anxiety Disord, 22, 877, 10.1016/j.janxdis.2007.09.003 · DOI
  39. Sevilla-Cermeño, 2019, Insomnia in pediatric obsessive–compulsive disorder: prevalence and association with multimodal treatment outcomes in a naturalistic clinical setting, Sleep Med, 56, 104, 10.1016/j.sleep.2018.12.024 · DOI
  40. Sharma, 2016, Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports, BMJ, 352
  41. Strawn, 2017, Placebo response in pediatric anxiety disorders: results from the Child/Adolescent Anxiety Multimodal Study, J Child Adolesc Psychopharmacol, 27, 501, 10.1089/cap.2016.0198 · DOI · Paper page
  42. Dobson, 2016, Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation, J Child Adolesc Psychopharmacol, 26, 686, 10.1089/cap.2015.0192 · DOI · Paper page
  43. Walkup, 2017, Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies, Am J Psychiatry, 174, 1, 10.1176/appi.ajp.2017.16091059 · DOI · Paper page

Cited by

See all 56

Metadata

Authors
Mills, J. A., & Strawn, J. R.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2020-11
Volume
59
Issue
11
Pages
1240-1251
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2984602026
Cited by
56
References
16
FWCI
4.76
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Institute of Child Health and Human Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis. https://app.cochat.ai/papers/10.1016/j.jaac.2019.10.013
The paper
Mills, J. A., & Strawn, J. R. (2020). Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2019.10.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.